Buy Online or Call 1-866-267-4263 |
| |
| AMA PRA Category 1 Credits™ |
| "Excellent course. I most liked the honest answers given by the speakers. Both of them master how to explain difficult topics in a very practical and helpful approach for primary physicians. All of the topics covered were useful." |
| Hugo Juarbe M.D. |
|
|
|
|
Home
Live Seminars
About the Program
Quick Order
Hotel Registration
Auto Rental
Accreditation
Cancellation Policy
Testimonials
Video DVDs
MP3s/Audio CDs
Subscribe
Request Brochure
Hold Seat
Testing Online
Faculty
Resources
Contact Us
|
|
|
|
by Thomas P. Olenginski, M.D., F.A.C.P. - Geisinger Medical Center, Geisinger Health System; Associate, Department of Rheumatology, Danville, PA and Frederick Sunderlin, M.D. - Jefferson Medical College, Thomas Jefferson University; Clinical Professor of Medicine; Associate, Department of Endocrinology, Geisinger Medical Center; Adjunct Professor of Medicine, Temple University School of Medicine; Clinical Professor, School of Graduate Studies, Lock Haven University, Lock Haven, PA.
Learning Objectives
What do our past participants have to say?
Refer a Colleague to Our Website
|
|
|
|
| EDUCATIONAL GAP AND NEEDS ANALYSIS STATEMENT: There is a need for the Primary Care Practitioner to be current in the specialties of Rheumatology and Endocrinology as evidenced by our participant evaluation forms and needs collection data that also include literature searches. These two areas of medicine have been combined in one presentation in an effort to cover the most important and commonly seen patient problems that are challenging PCPs today. Topics such as Diabetes, Thyroid Disease, Rheumatoid Arthritis, Osteoporosis and other diseases that inter-relate to each specialty will be taught due to the new diagnostic modalities and treatment guidelines that are now employed to improve patient outcomes.
| | Day 1 |
Osteoporosis 101: DXA and New WHO FRAX Model. Osteoporosis 102: Case Studies. Management of Type 1 Diabetes. Treatment Strategies in Type 2 Diabetes. |
| Day 2 |
Polycystic Ovary Syndrome. Adrenal Case Studies. Gout and Pseudogout: Acute Arthritis Visits to the Office/ER. Early Recognition and Treatment of Rheumatoid Arthritis (RA). |
| Day 3 |
Osteoarthritis: A Case-Based Approach. Doc, I Hurt All Over! The Fibromyalgia Syndrome. The Dyslipidemias: Evidence-Based Decision Making. Disorders of Calcium Metabolism. |
| Day 4 |
Thyroid Case Studies, Parts I & II. Rheumatology Pearls. Lupus: When to Consider It, and How to Test for and Treat. |
| Day 5 |
Polymyalgia Rheumatica and Giant Cell Arteritis. Recognition and Treatment of Spondyloarthropathies. Male Hypogonadism: Clinical Features. Pituitary Potpourri. |
|
|
|
Endocrinology and Rheumatology: The Most Useful Topics in Both Specialties
January 12-16, 2009
Location: Hyatt Regency Sarasota, Florida
OBJECTIVES
| OVERALL OBJECTIVES: The overall objective is to provide the participant with practical and clinically relevant information. Upon completion of this CME activity, the physician or healthcare provider should be able to describe the current approach to formulating differential diagnoses, diagnostic, therapeutic, and preventive management of the various disciplines presented. |
| SPECIFIC OBJECTIVES
| | Day 1 | Osteoporosis 101: DXA and New WHO FRAX Model. - Upon completion of this session, the participant should be able to:
| 1. | Predict fracture risk with DXA and clinical risks.
| | 2. | Recognize clinical indications for DXA.
| | 3. | Appreciate the new recommendations of the National Osteoporosis Foundation (Feb. 2008).
| | 4. | Utilize WHO 10 year Absolute Fracture Risk Model (WHO FRAX).
| | Osteoporosis 102: Case Studies. - Upon completion of this session, the participant should be able to:
| | 1. | List the current FDA approved treatments.
| | 2. | Appreciate potential side effects of therapies.
| | 3. | Respect the importance of Vertebral Fracture Assessment (VFA) and implications of fracture.
| | 4. | Employ the WHO FRAX Absolute Fracture Risk Tool and realize its limitations.
| | Management of Type 1 Diabetes. - Upon completion of this session, the participant should be able to:
| | 1. | Review current diagnostic criteria for the diagnosis of diabetes.
| | 2. | Discuss new insulin regimens for intensive glucose control.
| | 3. | Screen for and manage cardiovascular complications of diabetes based on evidence-based studies.
| | Treatment Strategies in Type 2 Diabetes. - Upon completion of this session, the participant should be able to:
| | 1. | Describe new pharmacologic agents available for glucose control.
| | 2. | Apply concepts of pathophysiology to the selection of pharmacotherapy for Type 2 Diabetes.
| | 3. | Discuss a cost-effective approach to the management of diabetic complications.
|
| | Day 2 | Polycystic Ovary Syndrome. - Upon completion of this session, the participant should be able to:
| 1. | Review current concepts in risk factors and pathophysiology.
| | 2. | Develop a simple laboratory screening process for diagnosis.
| | 3. | Apply our understanding of pathophysiology to design a treatment strategy.
| | Adrenal Case Studies. - Upon completion of this session, the participant should be able to:
| | 1. | Discuss the evaluation of the incidental adrenal mass.
| | 2. | Diagnose and treat adrenal insufficiency.
| | 3. | Manage patients with excessive adrenal steroid levels.
| | Gout and Pseudogout: Acute Arthritis Visits to the Office/ER. - Upon completion of this session, the participant should be able to:
| | 1. | Define the common presenting symptoms of crystalline arthritis.
| | 2. | Differentiate gout or pseudogout from septic arthritis.
| | 3. | Apply diagnostic arthrocentesis and crystal analysis in the evaluation.
| | 4. | Discriminate and apply the treatment principles in primary care.
| | Early Recognition and Treatment of Rheumatoid Arthritis (RA). - Upon completion of this session, the participant should be able to:
| | 1. | Recognize the early clinical manifestations of RA.
| | 2. | Utilize and apply available diagnostic testing.
| | 3. | Employ and distinguish the available DMARD therapies.
| | 4. | Recall the benefits of early Rheumatology referral.
| | 5. | Differentiate Biologic DMARD therapies.
|
| | Day 3 | Osteoarthritis: A Case-Based Approach. - Upon completion of this session, the participant should be able to:
| 1. | Utilize case studies to recognize the clinical signs and symptoms.
| | 2. | Appreciate diagnostic x-ray features.
| | 3. | Apply case studies to initiate treatment strategies.
| | Doc, I Hurt All Over! The Fibromyalgia Syndrome. - Upon completion of this session, the participant should be able to:
| | 1. | Recognize the common and non-specific symptoms of this malady.
| | 2. | Recall the lack of diagnostic test specificity in FMS.
| | 3. | Differentiate FMS from other rheumatic syndromes.
| | 4. | Initiate symptom-based treatment in FMS.
| | The Dyslipidemias: Evidence-Based Decision Making. - Upon completion of this session, the participant should be able to:
| | 1. | Discuss landmark outcomes studies in reducing cardiovascular risk.
| | 2. | Review the available lipid lowering therapies.
| | 3. | Apply evidence based protocols to at-risk patients.
| | Disorders of Calcium Metabolism. - Upon completion of this session, the participant should be able to:
| | 1. | Discuss the differential diagnosis of hypercalcemia.
| | 2. | Apply a cost effective workup to elevated calcium states.
| | 3. | Evaluate hypocalcemic disorders using common laboratory studies.
|
| | Day 4 | Thyroid Case Studies, Parts I & II. - Upon completion of this session, the participant should be able to:
| 1. | Review the etiologies and pathogenesis of hyper and hypothyroidism.
| | 2. | Apply cost effective principles in the laboratory evaluation of thyroid conditions.
| | 3. | Design effective treatment protocols for various thyroid conditions.
| | Rheumatology Pearls. - Upon completion of this session, the participant should be able to:
| | 1. | Apply relevant Rheumatology take-home points to daily primary care.
| | Lupus: When to Consider It, and How to Test for and Treat. - Upon completion of this session, the participant should be able to:
| | 1. | Recall the common presenting signs and symptoms.
| | 2. | Appreciate the limits of serologic testing methods.
| | 3. | Recognize clinical ‘subgroups’ of lupus.
| | 4. | Recall and initiate treatment strategies for SLE.
|
| | Day 5 | Polymyalgia Rheumatica and Giant Cell Arteritis. - Upon completion of this session, the participant should be able to:
| 1. | Recognize the clinical signs and symptoms of PMR and GCA.
| | 2. | Employ laboratory and other diagnostic testing methods.
| | 3. | Recall the clinical indications for temporal artery biopsy.
| | 4. | Initiate early therapy and appraise possible treatment complications.
| | Recognition and Treatment of Spondyloarthropathies. - Upon completion of this session, the participant should be able to:
| | 1. | Recognize the unique clinical signs and symptoms of this arthritis family.
| | 2. | Utilize NSAID and DMARD therapies.
| | 3. | Appreciate diagnostic x-ray features.
| | Male Hypogonadism: Clinical Features. - Upon completion of this session, the participant should be able to:
| | 1. | Discuss the concept of “male menopause”.
| | 2. | Design a cost-effective strategy to investigate causes of male hypogonadism.
| | 3. | Treat various endocrine conditions arising in men.
| | Pituitary Potpourri. - Upon completion of this session, the participant should be able to:
| | 1. | Provide a differential diagnosis based on clinical features.
| | 2. | Formulate a laboratory workup using a “best test” approach.
| | 3. | Discuss treatment options.
|
|
|